Outlook Therapeutics (NASDAQ: OTLK) announce first and only approved ophthalmic formulation of bevacizumab (for treatment of wet AMD) in the EU and UK.
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company based in Iselin, New Jersey, USA, has announced that the UK NICE (National Institute for Health and… Read More »Outlook Therapeutics (NASDAQ: OTLK) announce first and only approved ophthalmic formulation of bevacizumab (for treatment of wet AMD) in the EU and UK.